Sanofi (SNYNF) Total Non-Current Liabilities (2009 - 2025)
Sanofi's (SNYNF) quarterly Total Non-Current Liabilities came in at $31.1 billion in Q4 2025, up 13.04% year-on-year from $27.5 billion in Q4 2024, and up 7.37% quarter-over-quarter from $29.0 billion in Q2 2025.
Sanofi (SNYNF) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Sanofi has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $31.1 billion for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $31.1 billion, up 13.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.1 billion (up 13.04% YoY), and the FY2025 annual result was $31.1 billion, up 13.04% from the prior year.
- Total Non-Current Liabilities came in at $31.1 billion for Q4 2025 at Sanofi, up from $29.0 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $35.9 billion in Q2 2021 to a low of $27.5 billion in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $30.0 billion (2023), against an average of $30.5 billion.
- Across the five-year window, Total Non-Current Liabilities dropped 17.73% in 2022 and grew 13.04% in 2025, its largest moves.
- Sanofi's Total Non-Current Liabilities stood at $34.2 billion in 2021, then decreased by 17.73% to $28.2 billion in 2022, then climbed by 6.64% to $30.0 billion in 2023, then fell by 8.25% to $27.5 billion in 2024, then increased by 13.04% to $31.1 billion in 2025.
- The last three Total Non-Current Liabilities figures came in at $31.1 billion (Q4 2025), $29.0 billion (Q2 2025), and $27.5 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.14 Bn |
| Jun 30, 2025 | 29.00 Bn |
| Dec 31, 2024 | 27.55 Bn |
| Jun 30, 2024 | 28.79 Bn |
| Dec 31, 2023 | 30.02 Bn |
| Jun 30, 2023 | 30.06 Bn |
| Dec 31, 2022 | 28.15 Bn |
| Jun 30, 2022 | 30.35 Bn |
| Dec 31, 2021 | 34.22 Bn |
| Jun 30, 2021 | 35.90 Bn |
| Dec 31, 2020 | 38.01 Bn |
| Jun 30, 2020 | 36.93 Bn |
| Dec 31, 2019 | 272.41 Mn |
| Jun 30, 2019 | 39.13 Bn |
| Dec 31, 2018 | 39.95 Bn |
| Sep 30, 2018 | 426.87 Mn |
| Jun 30, 2018 | -35.80 Mn |
| Mar 31, 2018 | 42.47 Bn |
| Dec 31, 2017 | 30.74 Bn |
| Jun 30, 2017 | 29.70 Bn |